Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: contrast agent, Gadolinium Clear all
Completed Not applicable Interventional Results available

Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors

NCT02956291
View directory record Official record
Conditions
Brain Tumor
Interventions
Magnetic Resonance Fingerprinting
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

NCT03250078
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
MRI/MRCP
Diagnostic Test
Lead sponsor
Nuvance Health
Other
Eligibility
50 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

NCT02933034
View directory record Official record
Conditions
ISCHEMIC CARDIOMYOPATHY
Interventions
Manganese-enhanced MRI contrast reagent, Gadolinium-enhanced MRI contrast reagent
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

NCT02092428
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Image Quality, Diagnostic Accuracy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 29, 2026, 1:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

NCT04867954
View directory record Official record
Conditions
Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
Interventions
Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

NCT03602339
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 29, 2026, 1:27 AM EDT
Active, not recruiting Not applicable Interventional

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

NCT04454450
View directory record Official record
Conditions
Ovarian Cancer, High Grade Ovarian Serous
Interventions
PET/MRI, Contrast enhanced CT
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Gadoterate in Patients With Renal Dysfunction

NCT02382380
View directory record Official record
Conditions
Renal Dysfunction
Interventions
Gadoterate, No Gadoterate
Drug · Other
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 29, 2026, 1:27 AM EDT
Terminated No phase listed Observational

PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning

NCT03286972
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
PET/MRI
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

NCT05915728
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

WISE CVD - Continuation (WISE HFpEF)

NCT02582021
View directory record Official record
Conditions
Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions
Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

NCT00908310
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Omniscan
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 29, 2026, 1:27 AM EDT
Suspended Phase 4 Interventional

Gadopiclenol in Contrast Enhanced MRI of the Prostate

NCT06226129
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gadopiclenol
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Results available

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

NCT01544166
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadobutrol (Gadavist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 29, 2026, 1:27 AM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00005065
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, motexafin gadolinium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 29, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional

Cardiac Allograft Remodeling and Effects of Sirolimus

NCT01889992
View directory record Official record
Conditions
Cardiac Hypertrophy, Immunosuppression
Interventions
Cardiac MRI, Coronary angiography with IVUS, Cardiac Allograft Remodeling, M-TOR Immunosuppression, Cardiac Biopsy C4D stain, Genetic Mechanism of M-TOR, Cardiopulmonary Exercise Test (CPET)
Radiation · Procedure · Other + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting Phase 1 Interventional

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880
View directory record Official record
Conditions
Epilepsy
Interventions
Mangafodipir, Gadolinium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Active, not recruiting Not applicable Interventional

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

NCT02156739
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Gadobutrol, Gadoxetate Disodium
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

NCT02783768
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, E-cigarettes
Interventions
E-cigarette, Sham, Hyperpolarized 3-Helium, Gadolinium
Device · Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting Early Phase 1 Interventional

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

NCT07634640
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Ferumoxytol infusion
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

Observing People With Desmoid-Type Fibromatosis

NCT04281381
View directory record Official record
Conditions
Desmoid Fibromatosis
Interventions
Cross-sectional imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

NCT06151223
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
Bio-specimen Collection: Blood, Bio-specimen Collection: Pancreatic Juice, MRI
Other · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed No phase listed Observational

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

NCT05937776
View directory record Official record
Conditions
Glioma
Interventions
Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 29, 2026, 1:27 AM EDT